WP
VNDA icon

Woodline Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Woodline Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.43M Buy
+207,666
New +$1.6M 0.01% 836

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners's VNDA Position: Q1 2026 in Review

Woodline Partners opened a new position in Vanda Pharmaceuticals (VNDA) in Q1 2026: 207,666 shares worth $1.43M. The stake represents 0.01% of the portfolio and ranks #836 among its holdings.

170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Woodline Partners held 207,666 shares of Vanda Pharmaceuticals worth $1.43M as of Q1 2026.
  • Vanda Pharmaceuticals was a new Woodline Partners position in Q1 2026.
  • Vanda Pharmaceuticals made up 0.01% of Woodline Partners's portfolio in Q1 2026, its #836 holding.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.